Thymoglobulin (ATG)

DRUG5 trials

Sponsors

M.D. Anderson Cancer Center, University Hospital, Lille, University of Wisconsin, Madison

Conditions

Acute Myeloid LeukemiaAntibody Mediated RejectionChronic Myeloid LeukemiaEnd Stage Renal DiseaseLeukemiaLymphomaMyelodysplastic SyndromeMyelofibrosis

Phase 2

Busulfan, Fludarabine, Clofarabine With Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia

CompletedNCT00469014

M.D. Anderson Cancer CenterAcute Myeloid Leukemia, Chronic Myeloid Leukemia, Myelodysplastic Syndrome

Start: 2006-09-30End: 2013-03-31Updated: 2021-01-26

Allogeneic Stem Cell Transplantation for Myelofibrosis and Myelodysplastic Syndrome

CompletedNCT00475020

M.D. Anderson Cancer CenterMyelofibrosis

Start: 2006-01-04End: 2017-10-04Updated: 2019-05-21

Thiotepa-Clofarabine-Busulfan With Allogeneic Stem Cell Transplant for High Risk Malignancies

CompletedNCT00857389

M.D. Anderson Cancer CenterLeukemia, Lymphoma, Stem Cell Transplantation

Start: 2009-03-02End: 2019-03-09Updated: 2020-04-07

Phase 3

Daclizumab Versus Thymoglobulin in Renal Transplant Recipients With High Immunological Risk

CompletedNCT00682292

University Hospital, LilleRenal Transplantation

Start: 2001-05-31End: 2006-11-30Updated: 2008-05-22

Phase 4

Belatacept in Kidney Transplantation of Moderately Sensitized Patients

WithdrawnNCT02130817

University of Wisconsin, MadisonAntibody Mediated Rejection, End Stage Renal Disease

Start: 2014-09-24End: 2015-10-09Updated: 2018-12-17